Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma
Milestone payment triggered by European Medicines Agency acceptance of marketing authorization application for rezafungin
Company eligible to receive up to an additional $108M in milestones from multiple existing partnerships based on successful completion of activities planned for the next two years
Related news for (CDTX)
- URGENT VENU Update + 52-Week High Movers
- Stocks in the News: June 23, 2025 — AI, Biotech, Bitcoin, and Bold M&A Moves Shape the Market
- Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025
- Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
- Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development